Request a Proposal
Welcome to Rapport, containing tips, truths, news and views, blogs, tweets, articles and films covering a range of topics currently affecting Research Partnership and the pharma market research world

How we supported forecasting for a new vaccine by identifying the optimal pricing strategy

How we supported forecasting for a new vaccine by identifying the optimal pricing strategy

Our client was looking to identify the price point that would maximise revenue from their new vaccine across 8 emerging markets in Latin America and Asia Pacific, as well as establish long-term projections for their forecasting model. In parallel, they needed to ensure widespread and rapid market penetration of the vaccine, taking into account factors such as consumer socio-economic group, age and household composition.
 

read more »

  • Posted by Pei Li Teh & Colin Tan
  • June 19, 2020
  • Webinars

Agile is a mind-set not a methodology

Agile is a mind-set not a methodology

We’ve all heard about how important it is to be agile. And the focus in pharmaceutical market research has been mainly on speed, and the methodologies and techniques that get us faster results. But we believe there’s more to being agile than just toolkits and technology.

read more »

  • Posted by Brett Gardiner, Rachel Howard & Suzan Serip
  • June 12, 2020
  • Articles

The unprecedented challenge of pricing a coronavirus vaccine

The unprecedented challenge of pricing a coronavirus vaccine

Using findings from our recent COVID-19 impact study, Market Access Directors Rachel Howard and Brett Gardiner and Consultant Suzan Serip explore the challenges of pricing a coronavirus vaccine. Read our latest article for pharmaphorum.

The optimal pricing strategy for a new vaccine involves setting a fair and sustainable price that enables the eligible population in need across the world to gain access, while also rewarding innovation and supporting further research and development. The need for a SARS-CoV-2 vaccine is arguably more urgent, and more global, than ever before for a vaccine. As the 130+ vaccine candidates currently in development progress through clinical testing, a key question for their manufacturers is how COVID-19 might be changing the equation when it comes to what a responsible pricing strategy might look like. At the same time, payers are also faced with needing to prepare and plan for how to react and manage this situation.

read more »

  • Posted by Rachel Howard, Brett Gardiner & Richa Munjal
  • June 8, 2020
  • Articles

Breaking policy and perceptual barriers: Biosimilars

Breaking policy and perceptual barriers: Biosimilars

Our specialist market access and Therapy Watch teams analyse RA prescribing data to identify how market access policies across Europe may have impacted the adoption of biosimilars. Read our latest article for pharmaphorum's Deep Dive.

Biologics are big business in Rheumatoid Arthritis (RA), with the first wave of TNF inhibitors Remicade (infliximab), Enbrel (etanercept) and Humira (adalimumab) all having achieved blockbuster sales since their launches in the early 2000s. In recent years, as patents started to expire, an increasing number of branded and generic pharmaceutical companies have launched biosimilars, offering meaningful discounts relative to the originators – an appealing proposition for strained healthcare systems under pressure to contain costs. Leveraging over two years of syndicated RA Therapy Watch data* from September 2017-December 2019 in France, Germany, UK, Italy, and Spain, we looked into what parallels could be drawn between country trends in biosimilar prescribing and individual market policies designed to promote their use.

read more »

Client Testimonial “Research Partnership is one of the best agencies working in China & Emerging Markets..."

“Research Partnership is one of the best agencies working in China & Emerging Markets. The project team was simply brilliant and very responsive to all client needs. They helped me to manage almost 15 countries and did an extremely wonderful job. Additionally, a fantastic support and co-ordination of the Scientific Publication we are aiming for. Simply the best!”

read more »